BR112014032583A8 - forma farmacêutica para liberação prolongada de substâncias ativas e seu processo de produção - Google Patents

forma farmacêutica para liberação prolongada de substâncias ativas e seu processo de produção

Info

Publication number
BR112014032583A8
BR112014032583A8 BR112014032583A BR112014032583A BR112014032583A8 BR 112014032583 A8 BR112014032583 A8 BR 112014032583A8 BR 112014032583 A BR112014032583 A BR 112014032583A BR 112014032583 A BR112014032583 A BR 112014032583A BR 112014032583 A8 BR112014032583 A8 BR 112014032583A8
Authority
BR
Brazil
Prior art keywords
pharmaceutical form
active substances
prolonged release
production process
active substance
Prior art date
Application number
BR112014032583A
Other languages
English (en)
Other versions
BR112014032583B1 (pt
BR112014032583A2 (pt
Inventor
Francas Gernot
Przyklenk Karl-Heinz
Original Assignee
Hennig Arzneimittel Gmbh & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hennig Arzneimittel Gmbh & Co filed Critical Hennig Arzneimittel Gmbh & Co
Publication of BR112014032583A2 publication Critical patent/BR112014032583A2/pt
Publication of BR112014032583A8 publication Critical patent/BR112014032583A8/pt
Publication of BR112014032583B1 publication Critical patent/BR112014032583B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

forma farmacêutica para liberação prolongada de substâncias ativas. a presente invenção refere-se a uma forma farmacêutica, que possibilita liberar uniformemente uma substância ativa por um período mais longo. a forma farmacêutica compreende um emulsificante e um motivo de estrutura de óxido de polialquileno. a forma farmacêutica é apropriada para liberar, além da primeira substância ativa, também uma segunda substância ativa. nesse caso, uma liberação uniforme é obtida, mesmo quando as duas substâncias ativas têm propriedades totalmente diferentes, no que se refere à sua solubilidade. também são descritos processos de produção para a forma farmacêutica e o uso da mesma.
BR112014032583-9A 2012-06-25 2013-06-24 Forma farmacêutica para liberação prolongada de substâncias ativas e seu processo de produção BR112014032583B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102012105512.2A DE102012105512A1 (de) 2012-06-25 2012-06-25 Arzneiform zur verlängerten Freisetzung von Wirkstoffen
DE102012105512.2 2012-06-25
PCT/EP2013/063163 WO2014001268A1 (de) 2012-06-25 2013-06-24 Arzneiform zur verlängerten freisetzung von wirkstoffen

Publications (3)

Publication Number Publication Date
BR112014032583A2 BR112014032583A2 (pt) 2017-06-27
BR112014032583A8 true BR112014032583A8 (pt) 2021-06-22
BR112014032583B1 BR112014032583B1 (pt) 2022-05-17

Family

ID=48670585

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014032583-9A BR112014032583B1 (pt) 2012-06-25 2013-06-24 Forma farmacêutica para liberação prolongada de substâncias ativas e seu processo de produção

Country Status (22)

Country Link
EP (1) EP2863891B1 (pt)
KR (1) KR102160837B1 (pt)
AU (1) AU2013283474B2 (pt)
BR (1) BR112014032583B1 (pt)
CA (1) CA2876294C (pt)
CO (1) CO7240370A2 (pt)
DE (1) DE102012105512A1 (pt)
EA (2) EA035815B1 (pt)
ES (1) ES2817248T3 (pt)
HR (1) HRP20201534T1 (pt)
HU (1) HUE050945T2 (pt)
IL (1) IL236465B (pt)
IN (1) IN2014MN02511A (pt)
LT (1) LT2863891T (pt)
MX (1) MX371143B (pt)
PH (1) PH12014502834A1 (pt)
PL (1) PL2863891T3 (pt)
PT (1) PT2863891T (pt)
RS (1) RS60872B1 (pt)
SI (1) SI2863891T1 (pt)
UA (1) UA116776C2 (pt)
WO (1) WO2014001268A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
LT2959887T (lt) * 2014-06-26 2019-03-12 Hennig Arzneimittel Gmbh&Co. Kg Vaistai galvos svaigimo, atsiradusio dėl įvairių priežasčių, gydymui
WO2016010771A1 (en) 2014-07-17 2016-01-21 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
JP2017531026A (ja) 2014-10-20 2017-10-19 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 徐放性乱用抑止性液体充填剤形
KR101625344B1 (ko) * 2015-12-21 2016-06-08 주식회사 유영제약 세레콕시브 및 둘록세틴을 함유하는 약제학적 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
IE80467B1 (en) * 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
DE69811233T2 (de) * 1997-10-27 2003-11-20 Merck Patent Gmbh Feste lösungen und dispersionen von eines schlecht wasserlöslichen wirkstoffes
US6368622B2 (en) * 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
CA2551254A1 (en) * 2003-12-31 2005-07-21 Pfizer Products Inc. Stabilized pharmaceutical solid compositions of low-solubility drugs, poloxamers, and stabilizing polymers
US20050281876A1 (en) * 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
DE102005014141B4 (de) * 2005-03-23 2006-12-21 Hennig Arzneimittel Gmbh & Co. Kg Tablettenförmige Retardzubereitung gegen Schwindel
WO2007056078A2 (en) 2005-11-02 2007-05-18 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2007086078A2 (en) * 2006-01-30 2007-08-02 Panacea Biotec Ltd. Novel pharmaceutical compositions and process of preparation thereof
CN101049309A (zh) * 2006-04-03 2007-10-10 陈茜 桂利嗪滴丸及其制备方法
PL2200588T3 (pl) * 2007-09-25 2019-09-30 Solubest Ltd. Kompozycje zawierające lipofilowe związki aktywne i sposób ich wytwarzania
AU2008334580A1 (en) * 2007-12-12 2009-06-18 Basf Se Salts of active ingredients with polymeric counter-ions
US20120134921A1 (en) * 2009-06-11 2012-05-31 Photocure Asa Solid compositions comprising 5-aminolevulinic acid
WO2011024029A1 (en) * 2009-08-24 2011-03-03 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Fast disintegrating dosage forms of cinnarizine and dimenhydrinate combination
DE102011051308A1 (de) * 2011-06-24 2012-12-27 Hennig Arzneimittel Gmbh & Co. Kg Herstellungsverfahren und Arzneiform
DE102011051304A1 (de) * 2011-06-24 2012-12-27 Hennig Arzneimittel Gmbh & Co. Kg Wirkstoffmatrix
DE102011053068A1 (de) * 2011-08-29 2013-02-28 Hennig Arzneimittel Gmbh & Co. Kg Darreichungsform mit stabilisierten Wirkstoffpartikeln

Also Published As

Publication number Publication date
RS60872B1 (sr) 2020-11-30
BR112014032583B1 (pt) 2022-05-17
LT2863891T (lt) 2020-12-10
EP2863891B1 (de) 2020-08-26
CA2876294A1 (en) 2014-01-03
KR20150041612A (ko) 2015-04-16
BR112014032583A2 (pt) 2017-06-27
PH12014502834B1 (en) 2015-02-02
MX2014015642A (es) 2015-08-05
CO7240370A2 (es) 2015-04-17
ES2817248T3 (es) 2021-04-06
PT2863891T (pt) 2020-09-25
EP2863891A1 (de) 2015-04-29
DE102012105512A1 (de) 2014-04-24
MX371143B (es) 2020-01-20
EA028064B1 (ru) 2017-10-31
EA035815B1 (ru) 2020-08-14
UA116776C2 (uk) 2018-05-10
CA2876294C (en) 2020-09-08
PH12014502834A1 (en) 2015-02-02
HUE050945T2 (hu) 2021-01-28
SI2863891T1 (sl) 2020-11-30
EA201500043A1 (ru) 2015-09-30
AU2013283474A1 (en) 2015-01-29
IN2014MN02511A (pt) 2015-07-17
IL236465B (en) 2020-06-30
KR102160837B1 (ko) 2020-09-29
HRP20201534T1 (hr) 2021-02-19
PL2863891T3 (pl) 2021-01-25
IL236465A0 (en) 2015-02-26
EA201792143A1 (ru) 2018-05-31
WO2014001268A1 (de) 2014-01-03
AU2013283474B2 (en) 2017-12-14

Similar Documents

Publication Publication Date Title
BR112014032583A8 (pt) forma farmacêutica para liberação prolongada de substâncias ativas e seu processo de produção
CR20150326A (es) Inhibidores de autotaxina
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
CL2013003019A1 (es) Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
CL2016001936A1 (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
CL2015001756A1 (es) Compuestos derivados de carbamoilpiridona policiclicos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion de vih en un humano que tiene o se encuentra en riesgo de tener la infeccion.
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
BR112015024411A2 (pt) desaza-purinonas macrocíclicas para o tratamento de infeções virais
CL2014002093A1 (es) Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
BR112015000615A8 (pt) Purinas macrocíclicas para o tratamento de infecções virais e composição farmacêutica que as compreende
GT201500053A (es) Composicion farmaceutica recubierta que contiene regorafenib
NI201400032A (es) Piridopirazinas anticancerígenas via la
BR112014029706A8 (pt) Composto, composição farmacêutica, e, uso de um composto
BR112014010183B8 (pt) Composto, composição farmacêutica, produto, e, uso de um composto
BR112017007123A2 (pt) derivados de tetrahidroisoquinolina
BR112017016311A2 (pt) derivados de 9h-pirrolo-dipiridina
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
BR112015031979A2 (pt) letermovir, formulação farmacêutica oral sólida, uso de uma formulação farmacêutica oral sólida, e processo para preparar letermovir.
CO2017006898A2 (es) Formulación de relación fija de insulina glargina/lixisenatida
BR112015030431A2 (pt) formulação de liberação modificada
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
CL2016000787A1 (es) Composición farmacéutica en forma de comprimido que comprende atazanavir y cobicistat; procedimiento de preparación; y uso de la composición para preparar un medicamento útil para tratar la infección por el virus de inmunodeficiencia humana (vih).
CL2015001881A1 (es) Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición.
BR112014020008A8 (pt) composição farmacêutica, uso da mesma, e, processo para a fabricação de uma formulação.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/06/2013, OBSERVADAS AS CONDICOES LEGAIS